# 7. Collagen, Bone Health, and Menopause: The formulation of the collagen you use matters!

- **Channel:** Dr. Mary Claire Haver, MD
- **URL:** https://www.youtube.com/watch?v=zKqt4kW2Mmo
- **Views:** 105,297
- **Upload date:** 2025-12-31
- **Length:** 2m 14s
- **Transcript method:** YouTube captions (yt-dlp android client on Studio)
- **Full transcript:** [transcripts/zKqt4kW2Mmo.txt](../transcripts/zKqt4kW2Mmo.txt)

## Summary

Haver’s longer collagen short (versus the thirty-two-second teaser). She states women lose about 30% of skin collagen in the first five years of menopause, describes finding Verisol randomised trials for wrinkles and skin appearance, then turning to Fortibone bioactive collagen for bone because of personal osteoporosis risk and poor tolerability of osteoporosis drugs. She summarises a small 2021 long-term observation (about thirty-one patients with multi-year DXA follow-up) and a larger 2018 randomised trial where 5 g/day of specific peptides improved spine density by roughly 3% and femoral-neck density by about 6.7% versus placebo decline. She discloses creating her Skin and Bone product combining Verisol and Fortibone. The explicit message—“the formulation of the collagen you use matters”—validates category interest while advertising a competitor SKU. For Ovitage this is both opportunity (oral peptides for menopause bone/skin are culturally accepted) and a brief to differentiate on ovine multi-protein composition, BCAA/cystine profile, NZ upcycling and patents rather than copying Verisol/Fortibone claim sets.

## Key claims (with timestamps)

- **[00:00:01]** ~30% skin collagen loss in first 5 years of menopause.
- **[00:00:30]** Verisol bioactive peptides: RCTs for wrinkles/skin appearance.
- **[00:00:46]** Fortibone 5 g/day associated with BMD improvement in osteopenic/osteoporotic postmenopausal women (2021 long-term observation).
- **[00:01:32]** 2018 study: ~3% spine and ~6.7% femoral-neck BMD increase vs placebo drop.
- **[00:02:00]** Her Skin & Bone product combines Verisol + Fortibone.

## Exact quotes

- “A woman will lose 30% of the collagen in her skin in the first 5 years of menopause.”
- “The formulation of the collagen you use matters.”
- “These patients took five grams of this specific bioactive collagen called Fortibone and saw statistically significant improvement in their bone density.”

## Relevance to Ovitage

Highest-detail influencer case for specific oral collagen peptides in menopause bone/skin—validates category. Also a competitive lesson: she sells branded bovine collagen peptides. Ovitage differentiates via ovine whole-skin multi-protein, higher follicle-linked BCAA/cystine, NZ upcycled sourcing and patents—not by copying Verisol/Fortibone study claims.

## Weak / lightly evidenced medical claims to flag

- Speaker has commercial conflict (own collagen SKU).
- Cited trials are modest-sized; fracture outcomes not established; ‘treatment of osteoporosis’ language exceeds typical supplement evidence standards.
- 30% skin-collagen figure is widely repeated in menopause media—verify primary citation before using in regulated markets.